In 2008, seven major market sales of anticonvulsants reached $13.6 billion, making it one of the largest therapeutic drug classes in the Pharmaceutical sector. However, generic incursion of second generation anticonvulsants will continue to increase the barrier to entry for prospective players, although viable commercial opportunities exist to optimize returns from this lucrative drug class market
Key reasons to purchase this title
- Quantify the performance of key marketed and pipeline anticonvulsant drugs in the seven major markets over the period 2008 to 2018.
- Dissect the split of the sales forecast by country, by molecule, by brand, and by indcation for key products
- Identify the leading brands in this drug class over the next 10 years and understand the key factors driving their success.
